{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:25:23Z","timestamp":1793982323141,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012569","name":"University of Toledo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK114006"],"award-info":[{"award-number":["DK114006"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK133203"],"award-info":[{"award-number":["DK133203"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG086161"],"award-info":[{"award-number":["AG086161"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ymthe.2025.07.046","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T15:44:53Z","timestamp":1753803893000},"page":"5231-5247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy"],"prefix":"10.1016","volume":"33","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance D.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-2800","authenticated-orcid":false,"given":"Rujun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.07.046_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.07.046_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","article-title":"Complement activation and effector pathways in membranous nephropathy","volume":"105","author":"Kistler","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40001-023-01096-5","article-title":"The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy","volume":"28","author":"Cheng","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ymthe.2025.07.046_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12882-019-1509-5","article-title":"Complement activation products in the circulation and urine of primary membranous nephropathy","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.046_bib8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.046_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib10","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","article-title":"Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy","volume":"56","author":"Berg","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases","volume":"21","author":"Gong","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.ymthe.2025.07.046_bib13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol. Dial Transpl."},{"key":"10.1016\/j.ymthe.2025.07.046_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymthe.2025.07.046_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1681\/ASN.2022050605","article-title":"Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy","volume":"34","author":"Chen","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1681\/ASN.2009101025","article-title":"Melanocortin 1 receptor agonists reduce proteinuria","volume":"21","author":"Lindskog","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib17","article-title":"THSD7A-associated membranous nephropathy involves both complement-mediated and autonomous podocyte injury","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/CS20200016","article-title":"Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling","volume":"134","author":"Qiao","year":"2020","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.ymthe.2025.07.046_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/srep27589","article-title":"MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy","volume":"6","author":"Qiao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.046_bib20","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1007\/s00018-020-03511-0","article-title":"Melanocortin 5 receptor signaling pathway in health and disease","volume":"77","author":"Xu","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2025.07.046_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.651236","article-title":"Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.kint.2025.01.009","article-title":"Melanocortin 5 receptor signaling protects against podocyte injury in proteinuric glomerulopathies","volume":"107","author":"Chen","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib23","article-title":"Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib24","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34004-7","article-title":"Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization","volume":"8","author":"Bergwall","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.046_bib26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.kint.2020.05.052","article-title":"Global transcriptomic changes occur in aged mouse podocytes","volume":"98","author":"Wang","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad289","article-title":"Early growth response 1 as a podocyte injury marker in human glomerular diseases","volume":"17","author":"Okabe","year":"2024","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymthe.2025.07.046_bib28","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.kint.2016.01.012","article-title":"Podocyte injury and its consequences","volume":"89","author":"Nagata","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2023.07.014","article-title":"Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy","volume":"207","author":"Wang","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ymthe.2025.07.046_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41419-022-04737-5","article-title":"Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.046_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.046_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1152\/physiolgenomics.00088.2009","article-title":"Transcriptional and physiological responses to chronic ACTH treatment by the mouse kidney","volume":"40","author":"Dunbar","year":"2010","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.ymthe.2025.07.046_bib34","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1101\/gr.155697.113","article-title":"Defining cell-type specificity at the transcriptional level in human disease","volume":"23","author":"Ju","year":"2013","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2025.07.046_bib35","first-page":"1425","article-title":"A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes","volume":"14","author":"Mukherjee","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002466","article-title":"Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome","volume":"3","author":"Skov","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.07.046_bib37","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/S0021-9258(19)50409-4","article-title":"Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue","volume":"267","author":"White","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.07.046_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107705","article-title":"PPARgamma\/PGC1alpha signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders","volume":"219","author":"Jamwal","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2025.07.046_bib39","first-page":"850","article-title":"The effect of ACTH on blood complement, gamma globulins, and fibrinogen","volume":"29","author":"Vaughan","year":"1950","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.ymthe.2025.07.046_bib40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1542\/peds.15.2.156","article-title":"Prolonged intermittent ACTH and cortisone therapy in the nephrotic syndrome; immunologic basis and results","volume":"15","author":"Lange","year":"1955","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2025.07.046_bib41","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203314531840","article-title":"Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB\/W F1 mouse model of systemic lupus erythematosus","volume":"23","author":"Decker","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.ymthe.2025.07.046_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.ymthe.2025.07.046_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057313","article-title":"Effect of NDP-alpha-MSH on PPAR-gamma and -beta expression and anti-inflammatory cytokine release in rat astrocytes and microglia","volume":"8","author":"Carniglia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.07.046_bib45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/pcmr.12980","article-title":"The alpha-melanocyte-stimulating hormone\/melanocortin-1 receptor interaction: A driver of pleiotropic effects beyond pigmentation","volume":"34","author":"Herraiz","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ymthe.2025.07.046_bib46","doi-asserted-by":"crossref","first-page":"3116S","DOI":"10.1093\/jn\/130.12.3116S","article-title":"Hormonal signaling and transcriptional control of adipocyte differentiation","volume":"130","author":"Morrison","year":"2000","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymthe.2025.07.046_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00467-023-06088-5","article-title":"Pioglitazone, a PPAR-Y agonist, as one of the new therapeutic candidates for C3 glomerulopathy","volume":"39","author":"Balestra","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-042921-102405","article-title":"Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases","volume":"75","author":"Miwa","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.07.046_bib49","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.046_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel Treatments Paradigms: Membranous Nephropathy","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2025.07.046_bib51","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.ekir.2022.04.067","article-title":"POS-045 Evaluating BCX9930, an Oral Factor D Inhibitor for Treatment of Complement-Mediated Kidney Disease: A Proof-of-Concept Study (RENEW)","volume":"7","author":"Nester","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2025.07.046_bib52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ekir.2019.10.007","article-title":"An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression","volume":"5","author":"Zand","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2025.07.046_bib53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ckj\/sfw045","article-title":"Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis","volume":"9","author":"Kittanamongkolchai","year":"2016","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymthe.2025.07.046_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000520387","article-title":"Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation","volume":"2","author":"Naseer","year":"2021","journal-title":"Glomerular Dis."},{"key":"10.1016\/j.ymthe.2025.07.046_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.108986","article-title":"Melanocortin receptor agonists suppress experimental autoimmune uveitis","volume":"218","author":"Ng","year":"2022","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2025.07.046_bib56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1006\/bbrc.2002.6739","article-title":"Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6","volume":"292","author":"Grieco","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.07.046_bib57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)80467-5","article-title":"Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides","volume":"91","author":"Chen","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.07.046_bib58","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.4049\/jimmunol.1300182","article-title":"Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice","volume":"191","author":"Lee","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.kint.2022.09.025","article-title":"Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy","volume":"103","author":"Guan","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155233","article-title":"GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease","volume":"133","author":"Baumann","year":"2022","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.ymthe.2025.07.046_bib61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1523-1755.2005.00430.x","article-title":"The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion","volume":"68","author":"Collino","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/jrr\/rraa062","article-title":"Rosiglitazone ameliorates radiation-induced intestinal inflammation in rats by inhibiting NLRP3 inflammasome and TNF-alpha production","volume":"61","author":"Hu","year":"2020","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.ymthe.2025.07.046_bib63","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/cns.13260","article-title":"Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke","volume":"25","author":"Li","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ymthe.2025.07.046_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.07.046_bib65","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0002-9440(10)64239-3","article-title":"A new method for large scale isolation of kidney glomeruli from mice","volume":"161","author":"Takemoto","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104506","article-title":"Peroxisome proliferator-activated receptor \u0263 agonist mediated inhibition of heparanase expression reduces proteinuria","volume":"90","author":"Garsen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.07.046_bib67","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","article-title":"Rosiglitazone ameliorates cisplatin-induced renal injury in mice","volume":"21","author":"Lee","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymthe.2025.07.046_bib68","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ajpath.2011.01.029","article-title":"Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARgamma","volume":"178","author":"Zhu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.07.046_bib69","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ki.2014.428","article-title":"Fine-tuning of NFkappaB by glycogen synthase kinase 3beta directs the fate of glomerular podocytes upon injury","volume":"87","author":"Bao","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.07.046_bib70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1681\/ASN.2015060672","article-title":"Kruppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers","volume":"28","author":"Mallipattu","year":"2017","journal-title":"J. Am. Soc. Nephrol. : JASN"},{"key":"10.1016\/j.ymthe.2025.07.046_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141848","article-title":"Age-related GSK3beta overexpression drives podocyte senescence and glomerular aging","volume":"132","author":"Fang","year":"2022","journal-title":"J. Clin. Invest."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:58Z","timestamp":1792788238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625005829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1525001625005829"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.046","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}